NCT05766410View on ClinicalTrials.gov

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Breast CancerHormone Receptor-positive Breast CancerHormone Therapy
Interventions
DRUG

Palbociclib

CDK4, 6 inhibitor

DRUG

Ribociclib

CDK4, 6 inhibitor

DRUG

Abemaciclib

CDK4, 6 inhibitor

DRUG

Letrozole

Endocrine therapy

Trial Locations (2)

100

RECRUITING

Department of Oncology, National Taiwan University Hospital, Taipei

RECRUITING

Department of Oncology,National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER